Indivior Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Indivior Pharmaceuticals, Inc. (INDV) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.00M, a 37.50% increase year-over-year.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.00M, a 50.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.00M, a 0.00% change year-over-year.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $8.00M, a 33.33% increase year-over-year.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.00M, a 8.33% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $24.00M, a 14.29% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $21.00M, a 31.25% increase from fiscal 2022.
- Indivior Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.00M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00M 10-Q · filed 2026-08-03 | $20.00M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $9.00M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $26.00M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $6.00M 10-Q · filed 2025-10-30 | $14.00M derived: sum of 2 quarters · filed 2026-08-03 | $20.00M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | $8.00M 10-Q · filed 2026-08-03 | $14.00M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $6.00M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $24.00M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $6.00M 10-Q · filed 2025-10-30 | $12.00M derived: sum of 2 quarters · filed 2025-10-30 | $18.00M derived: sum of 3 quarters · filed 2025-10-30 | |
| 2024-06-30 | $6.00M 10-Q · filed 2025-10-30 | $12.00M derived: sum of 2 quarters · filed 2025-10-30 | ||
| 2024-03-31 | $6.00M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $21.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $16.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |